Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Valvular Heart Disease

Free Subscription Articles published in Circulation Retrieve available abstracts of 87 articles: HTML format

Single Articles

September 2025
1. KRISHNASWAMY A, Reed GW
   Defining Optimal Treatment Strategies for Bicuspid Aortic Valve Stenosis With Balloon- and Self-Expandable Transcatheter Heart Valves.
   Circulation. 2025;152:658-660.
   PubMed    
   
   
   
2. WAGNILD JM, Bayliss C, Maier RH, Ogundimu E, et al
   Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
   Circulation. 2025 Sep 5. doi: 10.1161/CIRCULATIONAHA.125.074651.
   PubMed     Abstract available
   
   
   August 2025
3. MESSIKA-ZEITOUN D, Chu MWA, Bouchard D, Le Tourneau T, et al
   Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
   Circulation. 2025 Aug 31. doi: 10.1161/CIRCULATIONAHA.124.073674.
   PubMed     Abstract available
   
   
   
4. KENNEDY J, Blackman DJ, Dodd M, Poggesi A, et al
   Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
   Circulation. 2025 Aug 30. doi: 10.1161/CIRCULATIONAHA.125.076761.
   PubMed     Abstract available
   
   
   
5. JORGENSEN TH, Savontaus M, Willemen Y, Bleie O, et al
   Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.
   Circulation. 2025 Aug 30. doi: 10.1161/CIRCULATIONAHA.125.076678.
   PubMed     Abstract available
   
   
   
6. FEISTRITZER HJ, Ender J, Lauten P, Rudolph TK, et al
   Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial.
   Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076557.
   PubMed     Abstract available
   
   
   
7. GIACOPPO D, Alvarez-Covarrubias H, Xhepa E, Matsuda Y, et al
   Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.
   Circulation. 2025 Aug 18. doi: 10.1161/CIRCULATIONAHA.124.069323.
   PubMed     Abstract available
   
   
   
8. PARK SJ, Kim M, Son J, Jo HH, et al
   Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis.
   Circulation. 2025 Aug 13. doi: 10.1161/CIRCULATIONAHA.125.074560.
   PubMed     Abstract available
   
   
   June 2025
9. GENEREUX P, Lindman BR, Pibarot P
   New Classification to Describe Clinical Presentation in Aortic Stenosis: Stable, Progressive, and Acute Valve Syndrome.
   Circulation. 2025;151:1627-1629.
   PubMed    
   
   
   
10. BERRY JD, de Lemos JA
    Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?
    Circulation. 2025;151:1565-1567.
    PubMed    
    
    
    May 2025
11. PRABHU NK, Aykut B, Mensah-Mamfo M, Overbey DM, et al
    Partial Heart Transplantation: Early Experience With Pediatric Heart Valve Replacements That Grow.
    Circulation. 2025;151:1477-1490.
    PubMed     Abstract available
    
    
    
12. DESAI MY, Wolski K, Owens A, Geske JB, et al
    Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
    Circulation. 2025;151:1378-1390.
    PubMed     Abstract available
    
    
    
13. METRA M, Tomasoni D, Adamo M, Anker SD, et al
    Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions.
    Circulation. 2025;151:1342-1363.
    PubMed     Abstract available
    
    
    April 2025
14. VEKSTEIN AM, Wegermann ZK, Manandhar P, Mack MJ, et al
    Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry.
    Circulation. 2025 Apr 3. doi: 10.1161/CIRCULATIONAHA.124.071838.
    PubMed     Abstract available
    
    
    March 2025
15. LINDMAN BR, Pibarot P, Schwartz A, Oldemeyer JB, et al
    Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial.
    Circulation. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.125.074425.
    PubMed     Abstract available
    
    
    
16. TANGUTURI VK, Abou-Karam R, Cheng F, Duan R, et al
    Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: a Randomized Clinical Trial.
    Circulation. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074470.
    PubMed     Abstract available
    
    
    
17. KAR S, Makkar RR, Whisenant BK, Hamid N, et al
    Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial.
    Circulation. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074536.
    PubMed     Abstract available
    
    
    
18. MEISNER JK, Renberg A, Smith ED, Tsan YC, et al
    Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.
    Circulation. 2025;151:783-798.
    PubMed     Abstract available
    
    
    February 2025
19. ROSA M, Dupont A, Smadja DM, Soquet J, et al
    Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning.
    Circulation. 2025 Feb 24. doi: 10.1161/CIRCULATIONAHA.124.071954.
    PubMed     Abstract available
    
    
    
20. ZHANG B, Enriquez-Sarano M, Schaff HV, Michelena HI, et al
    Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy.
    Circulation. 2025 Feb 24. doi: 10.1161/CIRCULATIONAHA.123.066523.
    PubMed     Abstract available
    
    
    January 2025
21. PARK SJ, Kang DH
    Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e28.
    PubMed    
    
    
    
22. WANG J, Peng Y
    Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e27.
    PubMed    
    
    
    
23. GUDMUNDSDOTTIR HL, Axelsson Raja A, Rossing K, Rasmusen H, et al
    Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.
    Circulation. 2025;151:132-144.
    PubMed     Abstract available
    
    
    December 2024
24. TOMII D, Pilgrim T, Borger MA, De Backer O, et al
    Aortic Stenosis and Coronary Artery Disease: Decision-Making Between Surgical and Transcatheter Management.
    Circulation. 2024;150:2046-2069.
    PubMed     Abstract available
    
    
    November 2024
25. URENA M
    Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time.
    Circulation. 2024;150:1505-1507.
    PubMed    
    
    
    October 2024
26. RUDOLPH F, Geyer M, Baldus S, De Luca VM, et al
    Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial.
    Circulation. 2024 Oct 30. doi: 10.1161/CIRCULATIONAHA.124.072648.
    PubMed    
    
    
    
27. WEDIN JO, Naslund V, Rodin S, Simonson OE, et al
    Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis.
    Circulation. 2024 Oct 23. doi: 10.1161/CIRCULATIONAHA.124.070753.
    PubMed     Abstract available
    
    
    
28. MAURIZI N, Antiochos P, Owens A, Lakdwala N, et al
    Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry.
    Circulation. 2024;150:1377-1390.
    PubMed     Abstract available
    
    
    
29. BENKHOFF M, Barcik M, Mourikis P, Dahlmanns J, et al
    Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease.
    Circulation. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.123.067270.
    PubMed     Abstract available
    
    
    
30. HOEDEMAKERS S, Cosyns B, Droogmans S, Verbrugge FH, et al
    Response by Hoedemakers et al to Letter Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis".
    Circulation. 2024;150:e278-e279.
    PubMed    
    
    
    
31. JHA AK
    Letter by Jha Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis".
    Circulation. 2024;150:e276-e277.
    PubMed    
    
    
    September 2024
32. SANNINO A, Mahkmudova U
    Artificial Intelligence and Mitral Regurgitation: Friend or Foe?
    Circulation. 2024;150:934-937.
    PubMed    
    
    
    
33. 
    Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2024;150:e267.
    PubMed    
    
    
    
34. CRIBIER A, Eltchaninoff H
    Transcatheter Aortic Valve Implantation: Two Decades of a Revolutionary and Ongoing Odyssey.
    Circulation. 2024;150:821-822.
    PubMed    
    
    
    
35. RAMO J, Jurgens SJ, Kany S, Choi SH, et al
    Rare Genetic Variants in LDLR, APOB, and PCSK9 are Associated with Aortic Stenosis.
    Circulation. 2024 Sep 2. doi: 10.1161/CIRCULATIONAHA.124.070982.
    PubMed     Abstract available
    
    
    August 2024
36. SHRIDHAR P, Pal S, Clavere NG, Becker JR, et al
    Response by Shridhar et al to Letter Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy".
    Circulation. 2024;150:e201-e202.
    PubMed    
    
    
    
37. DAVID TE
    Perspectives on Heart Valve Repair.
    Circulation. 2024;150:661-662.
    PubMed    
    
    
    
38. SUN Y, Ren J
    Letter by Sun and Ren Regarding Article, "MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy".
    Circulation. 2024;150:e200.
    PubMed    
    
    
    
39. VRUDHULA A, Duffy G, Vukadinovic M, Liang D, et al
    High-Throughput Deep Learning Detection of Mitral Regurgitation.
    Circulation. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.124.069047.
    PubMed     Abstract available
    
    
    
40. GOEL K, Makkar R, Krishnaswamy A, Kapadia S, et al
    Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States.
    Circulation. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068847.
    PubMed     Abstract available
    
    
    July 2024
41. CARRIER L
    RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy.
    Circulation. 2024;150:299-301.
    PubMed    
    
    
    
42. YANG P, Lou Y, Geng Z, Guo Z, et al
    Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy.
    Circulation. 2024;150:283-298.
    PubMed     Abstract available
    
    
    June 2024
43. LONG A, Haggerty CM, Finer J, Hartzel D, et al
    Deep Learning for Echo Analysis, Tracking, and Evaluation of Mitral Regurgitation (DELINEATE-MR).
    Circulation. 2024 Jun 17. doi: 10.1161/CIRCULATIONAHA.124.068996.
    PubMed     Abstract available
    
    
    
44. SMALL AM, Yutzey KE, Binstadt BA, Voigts Key K, et al
    Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Jun 17. doi: 10.1161/CIR.0000000000001254.
    PubMed     Abstract available
    
    
    
45. QUAST C, Bonner F, Polzin A, Veulemans V, et al
    Aortic Valve Stenosis Causes Accumulation of Extracellular Hemoglobin and Systemic Endothelial Dysfunction.
    Circulation. 2024 Jun 5. doi: 10.1161/CIRCULATIONAHA.123.064747.
    PubMed     Abstract available
    
    
    
46. MCGURK KA, Bilgehan N, Ware JS
    Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.
    Circulation. 2024;149:1786-1788.
    PubMed    
    
    
    
47. OMMEN SR, Ho CY, Asif IM, Balaji S, et al
    2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
    Circulation. 2024;149:e1239-e1311.
    PubMed     Abstract available
    
    
    May 2024
48. EVANGELISTA A, Galian-Gay L, Guala A, Teixido-Tura G, et al
    Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial.
    Circulation. 2024 May 28. doi: 10.1161/CIRCULATIONAHA.123.067537.
    PubMed     Abstract available
    
    
    
49. KANG DH, Park SJ, Shin SH, Hwang IC, et al
    Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
    Circulation. 2024 May 1. doi: 10.1161/CIRCULATIONAHA.124.069144.
    PubMed     Abstract available
    
    
    April 2024
50. SHEN M, Wu JC
    Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells.
    Circulation. 2024;149:1457-1460.
    PubMed    
    
    
    
51. DAVIDSON LJ, Tang GHL, Ho EC, Fudim M, et al
    The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Apr 25. doi: 10.1161/CIR.0000000000001232.
    PubMed     Abstract available
    
    
    
52. LI B, Liu F, Chen X, Chen T, et al
    FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System.
    Circulation. 2024;149:1268-1284.
    PubMed     Abstract available
    
    
    February 2024
53. HERRMANN HC, Desai ND
    Incidence, Implications, and Treatment of Patients With Severe Aortic Stenosis and Small Aortic Annulus.
    Circulation. 2024;149:656-657.
    PubMed    
    
    
    
54. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
    mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
    Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
    PubMed     Abstract available
    
    
    
55. CRESCI S, Bach RG, Saberi S, Owens AT, et al
    Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Circulation. 2024;149:498-509.
    PubMed     Abstract available
    
    
    January 2024
56. HAN D, Zhou T, Li L, Ma Y, et al
    AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease.
    Circulation. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.065213.
    PubMed     Abstract available
    
    
    
57. TOPRICEANU CC, Pereira AC, Moon JC, Captur G, et al
    Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
    Circulation. 2024;149:107-123.
    PubMed     Abstract available
    
    
    December 2023
58. SHRIDHAR P, Glennon MS, Pal S, Waldron CJ, et al
    MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
    Circulation. 2023;148:1870-1886.
    PubMed     Abstract available
    
    
    November 2023
59. LIN Y, Yang Q, Lin X, Liu X, et al
    Extracellular Matrix Disorganization Caused by ADAMTS16 Deficiency Leads to Bicuspid Aortic Valve With Raphe Formation.
    Circulation. 2023 Nov 29. doi: 10.1161/CIRCULATIONAHA.123.065458.
    PubMed     Abstract available
    
    
    
60. ROWIN EJ, Link MS, Maron MS, Maron BJ, et al
    Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Circulation. 2023;148:1797-1811.
    PubMed     Abstract available
    
    
    
61. SEO K, Yamamoto Y, Kirillova A, Kawana M, et al
    Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-beta-Blocking R-Enantiomer Carvedilol.
    Circulation. 2023;148:1691-1704.
    PubMed     Abstract available
    
    
    
62. 
    Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;148:e185.
    PubMed    
    
    
    
63. ROGERS MA, Bartoli-Leonard F, Zheng KH, Small AM, et al
    Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.
    Circulation. 2023 Nov 8. doi: 10.1161/CIRCULATIONAHA.123.066822.
    PubMed     Abstract available
    
    
    October 2023
64. RODES-CABAU J, Ribeiro H, Mohammadi S, Serra V, et al
    Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial.
    Circulation. 2023 Oct 26. doi: 10.1161/CIRCULATIONAHA.123.067326.
    PubMed     Abstract available
    
    
    
65. KAPADIA SR, Krishnaswamy A, Whisenant B, Potluri S, et al
    Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients with Atrial Fibrillation.
    Circulation. 2023 Oct 24. doi: 10.1161/CIRCULATIONAHA.123.067312.
    PubMed     Abstract available
    
    
    
66. DAHLE G, Al-Atassi T, Kaneko T
    The Future of Cardiac Surgical Training in the Age of Transcatheter Valvular Interventions.
    Circulation. 2023;148:1295-1297.
    PubMed    
    
    
    
67. HARIRI E, Kassis N, Kapadia SR
    Letter by Hariri et al Regarding Article, "Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial".
    Circulation. 2023;148:1267-1268.
    PubMed    
    
    
    
68. HASIFIC S, Rasmussen LM, Dahl JS, Diederichsen ACP, et al
    Response by Hasific et al to Letter Regarding Article, "Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial".
    Circulation. 2023;148:1269-1270.
    PubMed    
    
    
    September 2023
69. JEX N, Greenwood JP, Cubbon RM, Rider OJ, et al
    Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.
    Circulation. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.063444.
    PubMed     Abstract available
    
    
    
70. FIGLIOZZI S, Georgiopoulos G, Masci PG
    Letter by Figliozzi et al Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum".
    Circulation. 2023;148:978-979.
    PubMed    
    
    
    
71. ESSAYAGH B, Benfari G, Antoine C, Grigioni F, et al
    Response by Essayagh et al to Letter Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum".
    Circulation. 2023;148:980-981.
    PubMed    
    
    
    
72. AYERS MP, Kramer CM
    Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics.
    Circulation. 2023;148:819-821.
    PubMed    
    
    
    
73. JOY G, Kelly CI, Webber M, Pierce I, et al
    Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy.
    Circulation. 2023;148:808-818.
    PubMed     Abstract available
    
    
    August 2023
74. REINDL M, Lechner I, Holzknecht M, Tiller C, et al
    Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR): A Randomized, Open-Label, Non-Inferiority Trial.
    Circulation. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066498.
    PubMed     Abstract available
    
    
    
75. PRAKASH SK, Michelena HI, Milewicz DM
    Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals.
    Circulation. 2023;148:648-650.
    PubMed    
    
    
    
76. 
    Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;148:e8.
    PubMed    
    
    
    
77. ABOU ALAIWI S, Roston TM, Marstrand P, Claggett BL, et al
    Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry.
    Circulation. 2023;148:394-404.
    PubMed     Abstract available
    
    
    July 2023
78. ARMSTRONG DWJ, Riley LA, Su YR, Shah AS, et al
    Myocardial Neprilysin Is Increased in Hypertrophic Cardiomyopathy.
    Circulation. 2023;148:167-169.
    PubMed    
    
    
    
79. BLASER MC, Buffolo F, Halu A, Turner ME, et al
    Multiomics of Tissue Extracellular Vesicles Identifies Unique Modulators of Atherosclerosis and Calcific Aortic Valve Stenosis.
    Circulation. 2023 Jul 10. doi: 10.1161/CIRCULATIONAHA.122.063402.
    PubMed     Abstract available
    
    
    
80. MONDA E, Limongelli G
    Letter by Monda and Limongelli Regarding Article, "The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy".
    Circulation. 2023;148:73.
    PubMed    
    
    
    June 2023
81. GLOTZBACH JP, Hanson HA, Tonna JE, Horns JJ, et al
    Familial Associations of Prevalence and Cause-Specific Mortality for Thoracic Aortic Disease and Bicuspid Aortic Valve in a Large-Population Database.
    Circulation. 2023 Jun 15. doi: 10.1161/CIRCULATIONAHA.122.060439.
    PubMed     Abstract available
    
    
    May 2023
82. GALPER BZ, Chinnakondepalli KM, Wang K, Magnuson EA, et al
    Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.062481.
    PubMed     Abstract available
    
    
    April 2023
83. GOLLMANN-TEPEKOYLU C, Graber M, Hirsch J, Mair S, et al
    Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification.
    Circulation. 2023 Apr 4. doi: 10.1161/CIRCULATIONAHA.122.063481.
    PubMed     Abstract available
    
    
    March 2023
84. RAKOWSKI H, Bataiosu R
    Can Novel Myosin Inhibitors Defer Septal Reduction Therapy in HCM? At What Risk and at What Cost?
    Circulation. 2023;147:864-866.
    PubMed    
    
    
    
85. DESAI MY, Owens A, Geske JB, Wolski K, et al
    Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Circulation. 2023;147:850-863.
    PubMed     Abstract available
    
    
    February 2023
86. TURER AT, Wang A
    Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy.
    Circulation. 2023;147:700-702.
    PubMed    
    
    
    
87. CONWAY J, Min S, Villa C, Weintraub RG, et al
    The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy.
    Circulation. 2023;147:718-727.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Valvular Heart Disease is free of charge.